Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| (NYSE: BHVN) | Delayed: 11.75 -0.06 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.81 | 52 Week High | $ | |||
| Open | $11.90 | 52 Week Low | $ | |||
| Day High | $12.16 | P/E | N/A | |||
| Day Low | $11.63 | EPS | $ | |||
| Volume | 1,443,718 | |||||
